Subject(s)
Carcinoma, Squamous Cell/pathology , Carcinoma/pathology , Facial Neoplasms/pathology , Keratoacanthoma/pathology , Adult , Biopsy , Humans , MaleABSTRACT
Lipoid proteinosis is a rare autosomal recessive disorder which may be seen within a family very occasionally. Herein, we report lipoid proteinosis in two sisters characterized by verrucous lesions and hoarseness of voice, dysphagia and multiple beaded papules along the margins of their eyelids, fissured lips and thick ferenulum.
ABSTRACT
AIM: The intent of our study was to determine the efficacy of oral naltrexone, an opioid antagonist, in the treatment of pruritus in patients with chronic eczema. METHODS: This double-blind, placebo-controlled study recruited 38 patients with eczema complaining from pruritus. Pruritus scores were evaluated. Patients were given placebo (n = 20) or naltrexone 50 mg (n = 18) for 2 weeks period. During the study, pruritus scores based on visual analogue scale system (VAS) were assessed three times: at the start of study, after 1 week, and after 2 weeks. RESULTS: In both groups, decreased VAS scores were observed, but naltrexone showed to be significantly more effective than placebo in decreasing VAS score after 1 week (P < 0.005) and 2 weeks (P < 0.001). CONCLUSION: Naltrexone is more effective than placebo in the treatment of pruritus in patient with eczema. Naltrexone might be considered as an adjunct treatment in the treatment of pruritus. However, further studies in this aspect are highly fostered.
Subject(s)
Dermatitis, Atopic/complications , Naltrexone/administration & dosage , Naltrexone/therapeutic use , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/therapeutic use , Pruritus/drug therapy , Pruritus/etiology , Administration, Oral , Adult , Aged , Aged, 80 and over , Dizziness/chemically induced , Dose-Response Relationship, Drug , Double-Blind Method , Female , Headache/chemically induced , Humans , Male , Middle Aged , Naltrexone/adverse effects , Narcotic Antagonists/adverse effects , Nausea/chemically induced , Pain Measurement , Treatment OutcomeABSTRACT
BACKGROUND: Macular amyloidosis is a primary form of skin amyloidosis with deposition of small to moderate amyloid material in the upper dermis and mild pigmentary incontinence with resultant clinical hyperpigmentation. OBJECTIVES: To determine the efficiency of Q-switched Nd:YAG laser (532 and 1064 nm) in reducing the pigmentations due to skin macular amyloidosis. METHODS: A prospective, side by side, controlled, clinical trial study was designed. Twenty subjects with clinical diagnosis and pathology confirmation of macular amyloidosis were treated with Q-switched Nd:YAG laser: 532 nm in a part of their plaques and with 1064 nm in another part of their plaques. Assessment of efficiency was done by colorimetric scores based on Mexameter measurement and also digital photographs before laser therapy and 8 weeks after treatment. RESULTS: Mexameter-based data analysis showed that the two lasers (Q-switched 532 and 1064 Nd:YAG) are effective in reducing the degree of macular amyloidosis patches pigmentation, and 532 nm is meaningfully more effective than 1064 nm in this matter. Photograph-based analysis showed that 90% of cases treated by 532 nm had good or very good response, and for the 1064 nm-treated patches, 60% of cases had the good or very good response. CONCLUSIONS: The results of study showed the net positive effect of Q-switched Nd:YAG laser, either 532 nm or 1064 nm, in pigment reduction of macular amyloidosis patches, but the 532-nm laser was more effective than 1064 laser.
